• Skip to primary navigation
  • Skip to main content

Stanford Alliance for Primary Immunodeficiency

Stanford University

  • SAPI
  • Stanford PI Clinic
  • Patient Support
    • Diagnosis
    • Treatment and Complications
    • School
    • Work
    • Parenting
    • Sibling
    • Lifestyle
    • Mentorship Program
    • PI Resources
      • Immune Deficiency Foundation (IDF)
      • Jeffrey Modell Foundation
      • Painted Turtle Camp
      • Make-A-Wish
      • Baxter IVIG
      • CSL Behring IVIG
  • Kids’ Zone
    • Kids’ Zone
    • Pre-Teen FAQ
    • Teen FAQ
  • PID Research
    • Butte Lab Immunology Research Projects
    • PID Research blog
  • Local Events
  • Donate

Blog

Overview of Immunodeficiency Disorders.

October 12, 2015 By Manish Butte

Overview of Immunodeficiency Disorders.

Immunol Allergy Clin North Am. 2015 Nov;35(4):599-623

Authors: Raje N, Dinakar C

Abstract
The spectrum of primary immunodeficiency disorders (PIDs) is expanding. It includes typical disorders that primarily present with defective immunity as well as disorders that predominantly involve other systems and show few features of impaired immunity. The rapidly growing list of new immunodeficiency disorders and treatment modalities makes it imperative for providers to stay abreast of the latest and best management strategies. This article presents a brief overview of recent clinical advances in PIDs.

PMID: 26454309 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome.

October 11, 2015 By Manish Butte

Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome.

J Clin Immunol. 2015 Oct 9;

Authors: Mócsai G, Gáspár K, Dajnoki Z, Tóth B, Gyimesi E, Bíró T, Maródi L, Szegedi A

Abstract
PURPOSE: Hyper-IgE syndrome (HIES) is a severe primary immunodeficiency, characterized by increased serum IgE levels as well as recurrent infections and atopic dermatitis (AD)-like skin lesions. AD is a chronic inflammatory skin disease with immunologic alterations (Th2-Th22 polarization) and characteristic skin barrier dysfunctions. Our aim was to investigate physicochemical skin barrier alterations and allergic sensitization in STAT3-HIES patients in order to explore whether skin barrier dysfunction can play a role in the eczematoid skin lesions in these patients.
METHODS: In our experiments STAT3 and FLG mutation analyses were performed in STAT3-HIES (n = 7) and AD (n = 49) patients. Laboratory parameters (LDH and Eos counts), immunologic alterations (Th17 cell counts), allergic sensitization (total and specific IgE levels, skin prick tests, and medical history records), skin barrier changes [transepidermal water loss (TEWL), skin pH], serum and stratum corneum thymic stromal lymphopoietin (TSLP) levels were also examined.
RESULTS: Impaired Th17 cell numbers, but normal physicochemical barrier functions, as well as serum and stratum corneum TSLP levels, were found in STAT3-HIES, while these parameters were significantly altered in AD patients. Allergic sensitization was detected in nearly all AD patients, while no signs of sensitization occurred in STAT3-HIES.
CONCLUSIONS: Our study demonstrated that the skin barrier functions of STAT3-HIES patients are not damaged and they differ significantly from the altered skin barrier functions of AD patients. A well-functioning physicochemical skin barrier may be one of the explanations on the contradiction between the extremely high total IgE levels and the lack of allergic sensitization in these patients. Our study underlines the importance of skin barrier in the development of allergic sensitization.

PMID: 26453584 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.

October 10, 2015 By Manish Butte

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.

Oncoimmunology. 2015 Oct;4(10):e1030560

Authors: Ferretti E, Di Carlo E, Ognio E, Guarnotta C, Bertoni F, Corcione A, Prigione I, Fraternali-Orcioni G, Ribatti D, Ravetti JL, Ponzoni M, Tripodo C, Pistoia V

Abstract
Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and OCI-Ly8 cell lines in Severe combined immunodeficiency (SCID)/Non Obese Diabetic (NOD) mice. We found that: (i) B-NHL cell fractions and tonsil GC B cells expressed IL-17RA/IL-17RC, (ii) IL-17A signaled in both cell types through NF-kBp65, but not p38, ERK-1/2, Akt or NF-kBp50/105, phosphorylation, (iii) IL-17A was expressed in T cells and mast cells from neoplastic and normal GC microenvironments, (iv) IL-17A rendered tonsil GC B cells competent to migrate to CXCL12 and CXCL13 by downregulating RGS16 expression; (v) IL-17A stimulated in vitro proliferation of primary B-NHL cells; (vi) IL-17A (1 μg/mouse-per dose) stimulated B-NHL growth in two in vivo models by enhancing tumor cell proliferation and neo-angiogenesis. This latter effect depended on IL-17A-mediated induction of pro-angiogenic gene expression in tumor cells and direct stimulation of endothelial cells. These data define a previously unrecognized role of human IL-17A in promoting growth of GC-derived B-NHL and modulating normal GC B cell trafficking.

PMID: 26451300 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Age-Dependent Defects of Regulatory B Cells in Wiskott-Aldrich Syndrome Gene Knockout Mice.

October 9, 2015 By Manish Butte

Age-Dependent Defects of Regulatory B Cells in Wiskott-Aldrich Syndrome Gene Knockout Mice.

PLoS One. 2015;10(10):e0139729

Authors: Yokoyama T, Yoshizaki A, Simon KL, Kirby MR, Anderson SM, Candotti F

Abstract
The Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by recurrent infections, thrombocytopenia, eczema, and high incidence of malignancy and autoimmunity. The cellular mechanisms underlying autoimmune complications in WAS have been extensively studied; however, they remain incompletely defined. We investigated the characteristics of IL-10-producing CD19+CD1dhighCD5+ B cells (CD1dhighCD5+ Breg) obtained from Was gene knockout (WKO) mice and found that their numbers were significantly lower in these mice compared to wild type (WT) controls. Moreover, we found a significant age-dependent reduction of the percentage of IL-10-expressing cells in WKO CD1dhighCD5+ Breg cells as compared to age-matched WT control mice. CD1dhighCD5+ Breg cells from older WKO mice did not suppress the in vitro production of inflammatory cytokines from activated CD4+ T cells. Interestingly, CD1dhighCD5+ Breg cells from older WKO mice displayed a basal activated phenotype which may prevent normal cellular responses, among which is the expression of IL-10. These defects may contribute to the susceptibility to autoimmunity with age in patients with WAS.

PMID: 26448644 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies.

October 9, 2015 By Manish Butte

The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies.

J Clin Immunol. 2015 Oct 7;

Authors: Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan KE, Tang ML

Abstract
There are now nearly 300 single-gene inborn errors of immunity underlying phenotypes as diverse as infection, malignancy, allergy, auto-immunity, and auto-inflammation. For each of these five categories, a growing variety of phenotypes are ascribed to Primary Immunodeficiency Diseases (PID), making PIDs a rapidly expanding field of medicine. The International Union of Immunological Societies (IUIS) PID expert committee (EC) has published every other year a classification of these disorders into tables, defined by shared pathogenesis and/or clinical consequences. In 2013, the IUIS committee also proposed a more user-friendly, phenotypic classification, based on the selection of key phenotypes at the bedside. We herein propose the revised figures, based on the accompanying 2015 IUIS PID EC classification.

PMID: 26445875 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

October 7, 2015 By Manish Butte

Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Clin Exp Immunol. 2015 Oct 6;

Authors: Elgizouli M, Lowe DM, Speckmann C, Schubert D, Hülsdünker J, Eskandarian Z, Dudek A, Schmitt-Graeff A, Wanders J, Jørgensen SF, Fevang B, Salzer U, Nieters A, Burns S, Grimbacher B

Abstract
The gene PIK3CD codes for the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ) and is expressed solely in leukocytes. Activating mutations of PIK3CD have been described to cause an autosomal dominant immunodeficiency that shares clinical features with common variable immunodeficiency (CVID). We screened a cohort of 669 molecularly undefined primary immunodeficiency patients for five reported mutations (four gain of function mutations in PIK3CD and a loss of function mutation in PIK3R1) using pyrosequencing. PIK3CD mutations were identified in three siblings diagnosed with CVID and two sporadic cases with a combined immunodeficiency (CID). The PIK3R1 mutation was not identified in the cohort. Our patients with activated PI3Kδ syndrome (APDS) showed a range of clinical and immunological findings, even within a single family, but shared a reduction in naïve T cells. PIK3CD gain of function mutations are more likely to occur in patients with defective B and T cell responses and should be screened for in CVID and CID but are less likely in patients with a pure B cell/hypogammaglobulinaemia phenotype. This article is protected by copyright. All rights reserved.

PMID: 26437962 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Highlighting the problematic reliance on CD18 for diagnosing leukocyte adhesion deficiency type 1.

October 6, 2015 By Manish Butte

Highlighting the problematic reliance on CD18 for diagnosing leukocyte adhesion deficiency type 1.

Immunol Res. 2015 Oct 5;

Authors: Levy-Mendelovich S, Rechavi E, Abuzaitoun O, Vernitsky H, Simon AJ, Lev A, Somech R

Abstract
Leukocyte adhesion deficiency type 1 (LAD-1) is an autosomal recessive primary immunodeficiency, hallmarked by defective polymorphonuclear transmigration. It is caused by mutations in the gene encoding CD18, which interfere with the CD18/CD11 heterodimerization and expression on leukocyte cell surface. LAD-1 diagnosis rests primarily on the measurement of CD18 expression. However, CD18 measurement entails its pitfalls. Here we present a cohort of ten LAD patients and a review of the relevant literature illustrating the difficulties in sole reliance on CD18 measurement for initial diagnosis. These include normal range expression in some mutations, great variability between patients with the same mutation and subjective interpretation of results. We think there is a need for additional markers as part of the initial LAD diagnostic algorithm. We suggest CD11a expression, which was near absent in all patients in our cohort. The dual use of CD18 and CD11a can increase testing sensitivity and prevent delayed diagnosis of LAD-1.

PMID: 26434744 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Diagnosis and Management of Cutaneous B-cell Lymphoma.

October 5, 2015 By Manish Butte

Diagnosis and Management of Cutaneous B-cell Lymphoma.

Dermatol Clin. 2015 Oct;33(4):835-840

Authors: Pinter-Brown LC

Abstract
The diagnosis of primary cutaneous B-cell lymphoma (CBCL) requires that the search for a more widespread lymphoma has been negative. The clinical presentation, outlook, and treatment options of the common types of CBCLs, with emphasis on differences or similarities to their nodal counterparts, are discussed. Treatment may range from observation to topical therapies to systemic therapies, depending on the histology, degree and area of skin involvement, patient performance, and comorbidities. Rare lymphomas, such as intravascular large B-cell lymphoma and Epstein-Barr virus-positive cutaneous lymphoproliferations that are associated with immunodeficiency, are also briefly described.

PMID: 26433853 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Good syndrome presenting with CD8+ T-Cell large granular lymphocyte leukemia.

October 3, 2015 By Manish Butte

Good syndrome presenting with CD8+ T-Cell large granular lymphocyte leukemia.

Oncotarget. 2015 Sep 29;

Authors: Caperton C, Agrawal S, Gupta S

Abstract
Good Syndrome is an adult-onset combined immunodeficiency defined by hypogammaglobulinemia, low or absent number of B cells, T cell deficiency and thymic tumor. We have characterized CD8+ T cells from a patient with Good syndrome that presented with CD8+T-cell large granular lymphocytic leukemia (LGL). Characterization of peripheral blood CD8+ T cells revealed that majority of CD8+ T cells were terminally differentiated effector memory phenotype (TEMRA; CD8+CCR7-CD45RA+), and were PD-1high (CD279), ICOSlow (CD278), and granzymehigh. Almost all CD8+ T cells were IFN-γ+. CD8 Treg (CD8+CD183+CCR7+CD45RA-) were decreased. TEMRA phenotype along with CD279high, demonstrates that these are exhausted CD8+ T cells. This phenotype along with CD278low may also explain severe T cell functional deficiency in our patient. In the present patient, T-LGL appears to be a clonal expansion of CD279+granzyme+IFN-γ+CD8+TEMRA cells. To best of our knowledge this is the first case of CD8+T-cell LGL leukemia associated with Good syndrome.

PMID: 26429871 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

The Prevalence of Selective Immunoglobulin M Deficiency (SIgMD) in Iranian Volunteer Blood Donors.

October 3, 2015 By Manish Butte

The Prevalence of Selective Immunoglobulin M Deficiency (SIgMD) in Iranian Volunteer Blood Donors.

Hum Immunol. 2015 Sep 28;

Authors: Entezari N, Adab Z, Zeydi M, Saghafi S, Jamali M, Kardar GA, Pourpak Z

Abstract
BACKGROUND: Selective Immunoglobulin M Deficiency (SIgMD) is known as a rare primary immunodeficiency characterized by an isolated deficiency of serum IgM. Other immunoglobulin levels and T-cell immunity are usually normal; although IgE may be elevated. SIgMD can be asymptomatic or with various bacterial and viral infections. It can also be associated with autoimmune diseases or malignancies. In the present study, we report for the first time, the prevalence of SIgMD in Iranian healthy adult population.
MATERIALS AND METHODS: A total of 3436 healthy donors were examined in the study; from August, 2006 to April, 2008. Serum IgM concentration was measured using the nephelometric method. Due to the normal range of serum IgM in Iranian adults (39-283mg/dl), we considered serum IgM less than 30 mg/dl as IgM deficiency.
RESULTS: Among 3436 participants, 65% were male and 34% were female; aging from 17 to 72 years (38.18±10.78). Thirteen individuals were detected as IgM deficient subjects with the male to female ratio of 11/2, the prevalence of 0.37% and the frequency of 1/265. The mean serum IgM level was 24±4.56 (16-29mg/dl) in these cases. Among 13 IgM-deficient subjects, 7 cases were available for evaluating the clinical manifestations. In addition to atopic dermatitis which was the most common symptom in these patients, others were allergic rhinitis, food allergy, urinary tract infection and skin fungal infection. Two patients had no history of infectious disease or atopic conditions.
CONCLUSION: In the present study we could determine the prevalence of SIgMD in our adult population (0.37%). The most common comorbid condition was atopy. Neither severe or life-threatening infections, nor autoimmune diseases (based on their history but we didn’t screened autoantibodies ourselves) or malignancies were found in these patients. Further evaluation is recommended to elucidate the prevalence of SIgMD among patients with recurrent infections.

PMID: 26429316 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 646
  • Page 647
  • Page 648
  • Page 649
  • Page 650
  • Interim pages omitted …
  • Page 715
  • Go to Next Page »

Copyright © 2026 · Genesis Framework by StudioPress · WordPress · Log in